These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 16394867)

  • 1. What is in store for your Crohn's patient?
    Weitzman G; Maltz C
    J Clin Gastroenterol; 2006 Feb; 40(2):93-5. PubMed ID: 16394867
    [No Abstract]   [Full Text] [Related]  

  • 2. Predictors of immunomodulator use as early therapy in pediatric Crohn's disease.
    Jacobstein DA; Mamula P; Markowitz JE; Leonard M; Baldassano RN
    J Clin Gastroenterol; 2006 Feb; 40(2):145-8. PubMed ID: 16394876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methotrexate in Crohn's disease.
    Rampton DS
    Gut; 2001 Jun; 48(6):790-1. PubMed ID: 11358896
    [No Abstract]   [Full Text] [Related]  

  • 4. Therapy modifies HLA-G secretion differently in Crohn's disease and ulcerative colitis patients.
    Zelante A; Borgoni R; Galuppi C; Cifalà V; Melchiorri L; Gullini S; Baricordi O; Rizzo R
    Inflamm Bowel Dis; 2011 Aug; 17(8):E94-5. PubMed ID: 21604331
    [No Abstract]   [Full Text] [Related]  

  • 5. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease.
    Sandborn WJ; Feagan BG; Hanauer SB; Lochs H; Löfberg R; Modigliani R; Present DH; Rutgeerts P; Schölmerich J; Stange EF; Sutherland LR
    Gastroenterology; 2002 Feb; 122(2):512-30. PubMed ID: 11832465
    [No Abstract]   [Full Text] [Related]  

  • 6. Neutrophil-lymphocyte ratio in Crohn's disease patients predicts sustained response to infliximab 52-week therapy.
    Wlodarczyk MK; Sobolewska AE; Stec-Michalska K; Fichna JJ; Wisniewska-Jarosinska ME
    J Gastrointestin Liver Dis; 2015 Mar; 24(1):127-8. PubMed ID: 25822447
    [No Abstract]   [Full Text] [Related]  

  • 7. Disease Phenotype, Activity and Clinical Course Prediction Based on C-Reactive Protein Levels at Diagnosis in Patients with Crohn's Disease: Results from the CONNECT Study.
    Kwon JH; Im JP; Ye BD; Cheon JH; Jang HJ; Lee KM; Kim YS; Kim SW; Kim YH; Song GA; Han DS; Kim WH; Kim JS
    Gut Liver; 2016 Jul; 10(4):595-603. PubMed ID: 27021506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orbital myositis and Crohn's disease.
    Zenone T
    Int J Rheum Dis; 2014 May; 17(4):481-2. PubMed ID: 24267905
    [No Abstract]   [Full Text] [Related]  

  • 9. 6-Mercaptopurine/Azathioprine remains an important contributor in managing Crohn's disease.
    Korelitz BI; Present DH
    J Crohns Colitis; 2014 Aug; 8(8):735-8. PubMed ID: 24462321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum calprotectin as a biomarker for Crohn's disease.
    Meuwis MA; Vernier-Massouille G; Grimaud JC; Bouhnik Y; Laharie D; Piver E; Seidel L; Colombel JF; Louis E;
    J Crohns Colitis; 2013 Dec; 7(12):e678-83. PubMed ID: 23845231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunosuppressive treatment of Crohn's disease].
    Kasper H; Auer I
    Dtsch Z Verdau Stoffwechselkr; 1976; 36(3-4):143-5. PubMed ID: 1021382
    [No Abstract]   [Full Text] [Related]  

  • 12. [A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators].
    Martreau P
    Gastroenterol Clin Biol; 2000 Dec; 24(12):1243-4. PubMed ID: 11277090
    [No Abstract]   [Full Text] [Related]  

  • 13. [Immunosuppressive therapy of ulcerative colitis and Crohn's disease].
    Reitzig P; Apostoloff E; Lisewski G; Spranger GD
    Dtsch Gesundheitsw; 1973; 28(5):238-40. PubMed ID: 4722981
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunosuppressive drugs in the treatment of Crohn's disease.
    Rutgeerts P; Baert F
    Eur J Surg; 1998 Dec; 164(12):911-5. PubMed ID: 10029386
    [No Abstract]   [Full Text] [Related]  

  • 15. Successful treatment of metastatic Crohn's disease with cyclosporine.
    Carranza DC; Young L
    J Drugs Dermatol; 2008 Aug; 7(8):789-91. PubMed ID: 18720698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunosuppressants and Crohn's disease.
    Goldstein F
    Gastroenterology; 1972 May; 62(5):1101-2. PubMed ID: 5029074
    [No Abstract]   [Full Text] [Related]  

  • 17. Medical therapy for refractory pediatric Crohn's disease.
    Faubion WA; Bousvaros A
    Clin Gastroenterol Hepatol; 2006 Oct; 4(10):1199-213. PubMed ID: 16872913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thalidomide for Crohn's disease.
    Fishman SJ; Feins NR; D'Amoto RJ; Folkman J
    Gastroenterology; 2000 Aug; 119(2):596. PubMed ID: 10960273
    [No Abstract]   [Full Text] [Related]  

  • 19. The debated role for thiopurines in Crohn's disease.
    Herrlinger KR; Stange EF
    J Crohns Colitis; 2014 Feb; 8(2):172-4. PubMed ID: 24342765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Table: drugs for Crohn's disease.
    Med Lett Drugs Ther; 2018 Jul; 60(1550):e115. PubMed ID: 30036354
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.